Show simple item record

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535
IDREF: 028739272
dc.contributor.authorDAIEN, Vincent
dc.contributor.authorFAURE, Celine
dc.contributor.authorTADAYONI, Ramin
dc.contributor.authorGIOCANTI-AUREGAN, Audrey
dc.contributor.authorDOT, Corinne
dc.contributor.authorKODJIKIAN, Laurent
dc.contributor.authorMASSIN, Pascale
dc.contributor.authorINVESTIGATORS, Apollon Study
dc.date.accessioned2022-11-29T08:40:44Z
dc.date.available2022-11-29T08:40:44Z
dc.date.issued2022-10-29
dc.identifier.issn2045-2322 (Electronic) 2045-2322 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/170413
dc.description.abstractEnAPOLLON (NCT02924311) was a prospective observational study to evaluate the effectiveness of intravitreal aflibercept (IVT-AFL) treatment of diabetic macular edema (DME) over 24 months in routine clinical practice in France. The primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study letters) by 12 months, and safety was monitored throughout the study. Of 402 patients enrolled across 61 participating clinics and hospitals in France, 168 patients were followed for at least 24 months and included in the effectiveness analyses (79 treatment-naïve and 89 previously treated). After 24 months of IVT-AFL treatment, the mean (± standard deviation [SD]) change in BCVA from baseline was + 6.5 (± 10.7) letters in treatment-naïve patients (p < 0.001) and + 1.6 (± 17.0) letters in previously treated patients (p = 0.415) from a baseline of 63.8 (± 13.6) and 60.5 (± 16.5) letters. The mean number of IVT-AFL treatments over 24 months was 11.3 (± 4.9) and 11.9 (± 4.7) for treatment-naïve and previously treated patients. This final analysis of the APOLLON study indicated that following 24 months of IVT-AFL treatment in routine clinical practice in France, treatment-naïve patients with DME achieved significant gains in visual acuity and previously treated patients maintained prior visual acuity gains.Trial registration number: NCT02924311.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enTwo-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41598-022-22838-1en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36309572en_US
bordeaux.journalScientific Reportsen_US
bordeaux.volume12en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03877004
hal.version1
hal.date.transferred2022-11-29T08:40:47Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Scientific%20Reports&amp;rft.date=2022-10-29&amp;rft.volume=12&amp;rft.issue=1&amp;rft.eissn=2045-2322%20(Electronic)%202045-2322%20(Linking)&amp;rft.issn=2045-2322%20(Electronic)%202045-2322%20(Linking)&amp;rft.au=KOROBELNIK,%20Jean-Francois&amp;DAIEN,%20Vincent&amp;FAURE,%20Celine&amp;TADAYONI,%20Ramin&amp;GIOCANTI-AUREGAN,%20Audrey&amp;rft.genre=article


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record